GPGrossPatternRESEARCH SYSTEM
SEC CHECK OPERATIONAL
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

RNST · Dec 31, 2025

RENASANT CORP. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration

State dimensions

Filing0000715072-26-000017Bank
Sequential deposit growth25thOwn-history percentile · N=20
Evidence method

Sequential · gp.financial.deposits

0.23% · CORE · VALID

Net-income growth40thOwn-history percentile · N=20
Evidence method

Yoy · gp.fundamentals.net_income

-7.26% · CORE · VALID

Interest-income growth70thOwn-history percentile · N=20
Evidence method

Yoy · gp.financial.interest_income

42.18% · CORE · VALID

Cash and equivalents50thOwn-history percentile · N=20
Evidence method

Level · gp.fundamentals.cash

$1.1B · CORE · VALID

Sequential loan growth20thOwn-history percentile · N=20
Evidence method

Sequential · gp.financial.loans

0.13% · CORE · VALID

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History37 statesSelf-history eligible
Period transition

What moved in the state?

Deposit Growth Increased
Previous
-0.73%
Current
0.23%
Delta
0.96%
Earnings Growth Increased
Previous
-17.48%
Current
-7.26%
Delta
10.23%
Interest Income Growth Decreased
Previous
53.29%
Current
42.18%
Delta
-11.11%
Liquidity Decreased
Previous
$1.1B
Current
$1.1B
Delta
-$13.1M
Loan Growth Decreased
Previous
2.49%
Current
0.13%
Delta
-2.36%
Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.
Research Graph

Related governed research

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.